The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients

Silva, Cláudia Bezerra da; Gonçales, Neiva Sellan Lopes; Pereira, Josiane Silveira Felix; Escanhoela, Cecília Amélia F.; Pavan, Maria Helena Postal; Gonçales, Fernando Lopes

doi:10.1590/s1413-86702004000600007

Cited by 27 publications

(31 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of occult B infection in this study was 9 (4.4%), which is higher than some studies (9,33) ; however, it should be stated that the results of some other researches showed a higher prevalence of OBI (8) . Sodhi et al (34) estimated that OBI incidence among 244 HBsAgnegative cancer patients before receiving chemotherapy was 1.9% (13 out of 690).…”

Section: Discussioncontrasting

confidence: 84%

Prevalence of Occult Hepatitis B Infection in Iranian Cancer Patients Before Chemotherapy Treatment

Baghbanian

Halvani

Roghani

et al. 2016

Arq. Gastroenterol.

View full text Add to dashboard Cite

Background Occult hepatitis B infection is characterized by negative hepatitis B surface antigen (HBsAg) and also detectable hepatitis B virus (HBV) -DNA, with or without hepatitis B core antibody (anti-HBc). HBV reactivation in individuals under immunosuppressive therapy is critical, occurring in occult HBV. Objective In this study, we aimed to determine the prevalence of occult HBV infection among hepatitis B surface antigen negative in cancer patients before receiving chemotherapy. Methods Sera from 204 cancer patients who were negative for HBsAg, were tested for anti-HBc antibodies. The samples that were negative for HBsAg but positive for anti-HBc also examined for HBV-DNA by polymerase chain reaction (PCR). Results Of the 204 HBsAg negative blood samples, 11 (5.4%) samples were positive for anti-HBc antibodies. HBV-DNA was detected in 9/11 (81%) of anti-HBc positive samples. Occult HBV infection in hematological cancers was more than solid cancers, 4.8% and 4.3% respectively. There was no significant difference in HBc antibody positivity based on vaccination, previous blood transfusions, history of familial hepatitis or biochemical parameters (ALT, AST, total and direct bilirubin levels) (P>0.05). Conclusion Screening of occult HBV infection by HBsAg, HBV DNA and anti HB core antibody should be suggested as a routine investigation in cancer patients before receiving chemotherapy.

show abstract

Section: Discussioncontrasting

confidence: 84%

Prevalence of Occult Hepatitis B Infection in Iranian Cancer Patients Before Chemotherapy Treatment

Baghbanian

Halvani

Roghani

et al. 2016

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Occult HBV infection has received much attention recently, since it has been detected in patients with hepatocarcinoma [18], in blood donors and transfused patients [19,20], and in patients infected with hepatitis C virus [21][22][23]. In chronic HCV patients on hemodialysis, the prevalence of occult HBV infection is not yet well known [22,24].…”

Section: Discussionmentioning

confidence: 99%

Occult hepatitis B virus infection in immunocompromised patients

Jardim¹,

Gonçales²,

Pereira³

et al. 2008

Braz J Infect Dis

Self Cite

View full text Add to dashboard Cite

Occult hepatitis B infection is characterized by hepatitis B virus (HBV) DNA in the serum in the absence of hepatitis B surface antigen (HBsAg). We assessed occult HBV infection prevalence in two groups of immunocompromised patients (maintenance hemodialysis patients and HIV-positive patients) presenting HBsAgnegative and anti-HBc positive serological patterns, co-infected or not by HCV. Thirty-four hemodialysis anti-HIV negative patients, 159 HIV-positive patients and 150 blood donors who were anti-HBc positive (control group) were selected. HBV-DNA was detected by nested-PCR. Occult hepatitis B infection was not observed in the hemodialysis patients group but was found in 5% of the HIV-patients and in 4% of the blood donors. Immunosuppression in HIV positive patients was not a determining factor for occult HBV infection. In addition, no significant relationship between HBV-DNA and HCV co-infection in the HIV-positive patient group was found. A lack of significant associations was also observed between positivity for HBV-DNA and CD4 count, viral load and previous lamivudine treatment in these HIV-positive patients.

show abstract

“…Meanwhile, we need to know more about the potential progression of occult hepatitis B, as well as its transmission, carcinogenesis [19] and association with hepatitis C [20].…”

Section: Discussionmentioning

confidence: 99%

Occult B infection in the Brazilian northeastern region: a preliminary report

Almeida¹,

Tavares-Neto²,

Trépo

et al. 2008

Braz J Infect Dis

View full text Add to dashboard Cite

A sentinel study on viral hepatitis is currently being carried out in the village of Cavunge in a semiarid rural region of the state of Bahia, northeastern Brazil. This study has identified individuals in whom anti-HBc IgG was the only serological marker for hepatitis B virus (HBV). This serological pattern may constitute evidence of occult HBV infection. This study Investigated the possibility of occult hepatitis B virus infection in individuals in a rural community who tested positive for anti-HBc IgG alone. A cross-sectional population-based study. ELISA III was performed on serum samples to test for serological viral markers, and ultrasensitive PCR (US-PCR) was used to assess viremia. Among the 1,536 serum samples, 3.6% (n=55) were positive for anti-HBc alone. Four years after this first serological survey, 31 of those 55 individuals (56.3%) were retested, and 11 (35.5%) remained anti-HBc positive alone. Two of these 31 (6.5%) were HBV-DNA positive based on US-PCR, with normal aminotransferase levels in both cases. Cases of occult hepatitis B infection were identified in this semiarid rural community of northeastern Brazil, where endemicity of HBV is moderate. Key-Words: Anti-HBc alone, hepatitis B virus, occult hepatitis B, ultrasensitive PCR.Approximately 400 million people worldwide are chronic hepatitis B carriers. Despite vaccination, serological tests performed in hemotherapy services, and programs for the prevention of sexually transmitted infections, the number of hepatitis B virus (HBV)-infected individuals remains high, with prevalence ranging from 0.1% to 20% [1].The serological marker most widely used to detect exposure to HBV is HBcAg IgG; however, this marker is unable to define the status of the HBV carrier [2]. In individuals in whom antibody against the core protein (anti-HBc IgG) is the only positive marker, there are various possible explanations for false-positive test results, including patients with past, resolved infection, in whom the antibody against hepatitis B surface antigen (anti-HBs) is not present, occult HBV infection due to mutation of the S gene, or very low viral replication [3]. In this last hypothesis, analysis for HBV-DNA is considered the most sensitive diagnostic method [4].Clearance of hepatitis B surface antigen (HBsAg) generally indicates seroconversion to anti-HBs and consequent remission of HBV infection [5]. However, several researchers have shown that seroconversion to anti-HBs is not necessarily indicative of virological cure. In this case, an occult, silent or latent hepatitis B infection may be characterized by presence of viral DNA alone, while the patient tests negative for HBsAg or anti-HBc [6]. A clear example is the diagnosis of this infection in patients with chronic hepatitis of undefined etiology (cryptogenic hepatitis), comorbid hepatitis C virus (HCV), HIV carriers, patients with chronic renal failure or patients with hepatocellular carcinoma [7,8]. There are also case reports of hepatitis B transmission following blood transfusion or organ donation...

show abstract

The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients

Cited by 27 publications

References 49 publications

Prevalence of Occult Hepatitis B Infection in Iranian Cancer Patients Before Chemotherapy Treatment

Prevalence of Occult Hepatitis B Infection in Iranian Cancer Patients Before Chemotherapy Treatment

Occult hepatitis B virus infection in immunocompromised patients

Occult B infection in the Brazilian northeastern region: a preliminary report

Contact Info

Product

Resources

About